- Conditions
- Moderate-to-Severe Atopic Dermatitis
- Interventions
- Nemolizumab
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,935 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 136
- States / cities
- Birmingham, Alabama • Guntersville, Alabama • Scottsdale, Arizona + 104 more
Location Directory
Clinical trials in Jacksonville, Florida
This page shows live ClinicalTrials.gov search results for Jacksonville, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
7623
Shown on this page
12
Current sort
Recently updated
Location scope
Jacksonville, FL
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 289–300 of 7,623 matching trials in Jacksonville, FL.
Live ClinicalTrials.gov results.
Institutions in Jacksonville
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Advanced Dedifferentiated Liposarcoma, Locally Advanced Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Unresectable Dedifferentiated Liposarcoma
- Interventions
- Palbociclib, Cemiplimab, Magnetic Resonance Imaging, Computed Tomography, Biospecimen collection, Questionnaire Administration
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 194
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 146 more
- Conditions
- Coronary Restenosis
- Interventions
- SELUTION SLR 014 DEB, Standard of Care
- Device
- Lead sponsor
- M.A. Med Alliance S.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 418 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 34
- States / cities
- Loma Linda, California • Los Angeles, California • Torrance, California + 30 more
- Conditions
- Growth
- Interventions
- Extensively hydrolyzed casein formula (C-eHCF), commercially available, Extensively hydrolyzed casein formula (INV-eHCF)
- Other
- Lead sponsor
- Mead Johnson Nutrition
- Industry
- Eligibility
- 10 Days to 14 Days
- Enrollment
- 214 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Jonesboro, Arkansas • Harbor Beach, Florida + 8 more
- Conditions
- Thyroid Eye Disease, TED, Graves Orbitopathy
- Interventions
- linsitinib, Placebo
- Drug
- Lead sponsor
- Sling Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 18
- States / cities
- Glendale, Arizona • Beverly Hills, California • Canoga Park, California + 15 more
- Conditions
- Depressive Disorder, Treatment-Resistant
- Interventions
- AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination), Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Bellflower, California • Costa Mesa, California + 26 more
- Conditions
- Irritable Bowel Syndrome Characterized by Constipation
- Interventions
- Plecanatide, Placebo
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 1,054 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 155
- States / cities
- Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 142 more
- Conditions
- Diabetes Insipidus
- Interventions
- NDI-5001
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- Santa Ana, California • Jacksonville, Florida • San Antonio, Texas
- Conditions
- Hematopoietic Cell Transplantation Recipient, Leukemia, Solid Tumor
- Interventions
- Assessment of Therapy Complications, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Not listed
- Enrollment
- 25,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 163
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 124 more
- Conditions
- Low Vision Aids
- Interventions
- At Home Use
- Device
- Lead sponsor
- Brooks Rehabilitation
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Dravet Syndrome
- Interventions
- zorevunersen, Sham Comparator
- Drug · Other
- Lead sponsor
- Stoke Therapeutics, Inc
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 23 more
- Conditions
- Obesity, Overweight, Chronic Weight Management, Type2 Diabetes Mellitus
- Interventions
- aleniglipron, Placebo
- Drug
- Lead sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 1,100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 68 more